CagriSema (Cagrilintide B and Semaglutide I) Clinical Trials (2026): 7 Studies for Obesity & Diabetes Mellitus, Type 2
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
7 CagriSema (Cagrilintide B and Semaglutide I) clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Obesity & Diabetes Mellitus, Type 2) and 929 total planned enrollment. 3 Phase 3 CagriSema (Cagrilintide B and Semaglutide I) trials and 2 Phase 2 are listed. 1 CagriSema (Cagrilintide B and Semaglutide I) clinical trial is actively recruiting at 14 U.S. sites across 8 states. Most recent activity: NCT07282613 (Mar 2030).
Where to Participate: All CagriSema (Cagrilintide B and Semaglutide I) Trial Sites in the U.S. (14 sites across 8 states)
Every actively recruiting CagriSema (Cagrilintide B and Semaglutide I)trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Encore Medical Research Boynton Beach | Boynton Beach33436 | NCT07282613 | Map |
| FL | Nemours Chld Clnc Jacksonville | Jacksonville32207 | NCT07282613 | Map |
| FL | Innovus Clinical | Kissimmee34741 | NCT07282613 | Map |
| FL | D&H National Research Centers | Tamarac33321 | NCT07282613 | Map |
| FL | Clinical Research Trials of Florida | Tampa33607 | NCT07282613 | Map |
| GA | Columbus Research Foundation | Columbus31904 | NCT07282613 | Map |
| GA | Eastside Bariatric and Gen Surg | Snellville30078 | NCT07282613 | Map |
| IA | University of Iowa | Iowa City52242 | NCT07282613 | Map |
| MI | Great Lakes Research Inst. | Southfield48075 | NCT07282613 | Map |
| TN | LifeDoc Health | Memphis38115 | NCT07282613 | Map |
| TX | Amir Ali Hassan, MD, PA | Houston77089 | NCT07282613 | Map |
| TX | Consano Clinical Research, LLC | Shavano Park78231 | NCT07282613 | Map |
| VA | UVA Health Systems | Charlottesville22903 | NCT07282613 | Map |
| WA | Seattle Children's Research Institute | Seattle98105 | NCT07282613 | Map |
CagriSema (Cagrilintide B and Semaglutide I) clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | withdrawn | Total |
|---|---|---|---|---|---|
| P1 | 1 | 1 | 2 | ||
| P2 | 1 | 1 | 2 | ||
| P3 | 1 | 1 | 1 | 3 |
Recruiting CagriSema (Cagrilintide B and Semaglutide I) clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07282613 | REIMAGINEYOUNGA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | P3 | Diabetes Mellitus, Type 2 | 80 | Aug 2026 |
CagriSema (Cagrilintide B and Semaglutide I) clinical trials by indication
Diabetes Mellitus, Type 2 (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07282613 | REIMAGINEYOUNG | P3 | recruiting | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes |
| NCT07357740 | — | P2 | withdrawn | A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes |
| NCT06797869 | — | P2 | completed | A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy |
Obesity (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07011667 | — | P3 | active not recruiting | A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term |
| NCT07184086 | — | P1 | active not recruiting | A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet |
| NCT06716307 | — | P1 | completed | A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity |
Overweight (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07357766 | — | P3 | withdrawn | A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight |
CagriSema (Cagrilintide B and Semaglutide I) pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| REIMAGINEYOUNG | NCT07282613 | P3 | recruiting | Diabetes Mellitus, Type 2 | 80 | — |
Terminated and withdrawn CagriSema (Cagrilintide B and Semaglutide I) trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT07357766withdrawnA Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
- NCT07357740withdrawnA Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
All CagriSema (Cagrilintide B and Semaglutide I) trials (7)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07282613 | REIMAGINEYOUNG | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | P3 | recruiting | 80 | Novo Nordisk A/S | Aug 2026 |
| NCT07011667 | A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | P3 | active not recruiting | 609 | Novo Nordisk A/S | Jun 2025 | |
| NCT07184086 | A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet | P1 | active not recruiting | 80 | Novo Nordisk A/S | Sep 2025 | |
| NCT07357766 | A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight | P3 | withdrawn | 0 | Novo Nordisk A/S | Jun 2026 | |
| NCT07357740 | A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes | P2 | withdrawn | 0 | Novo Nordisk A/S | Aug 2026 | |
| NCT06797869 | A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | P2 | completed | 142 | Novo Nordisk A/S | Jan 2025 | |
| NCT06716307 | A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity | P1 | completed | 18 | Novo Nordisk A/S | Dec 2024 |
CagriSema (Cagrilintide B and Semaglutide I) clinical trials: frequently asked questions
- How many CagriSema (Cagrilintide B and Semaglutide I) clinical trials are there?
- 7 CagriSema (Cagrilintide B and Semaglutide I) clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 2 are marked completed.
- Are CagriSema (Cagrilintide B and Semaglutide I) clinical trials recruiting in 2026?
- Yes — 1 CagriSema (Cagrilintide B and Semaglutide I) trial is actively recruiting in 2026, with 14 U.S. sites across 8 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is CagriSema (Cagrilintide B and Semaglutide I) being studied for?
- CagriSema (Cagrilintide B and Semaglutide I) is being studied for Obesity, Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy, Overweight. The trials are grouped by indication on this page.
- What phase is CagriSema (Cagrilintide B and Semaglutide I) in?
- CagriSema (Cagrilintide B and Semaglutide I) clinical trials span 3 Phase 3, 2 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors CagriSema (Cagrilintide B and Semaglutide I) clinical trials?
- The lead sponsor across the most CagriSema (Cagrilintide B and Semaglutide I) trials is Novo Nordisk A/S. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming CagriSema (Cagrilintide B and Semaglutide I)as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: